Acadia Pharmaceuticals Inc (ACAD) is looking forward to a strong quarter

With 1.48 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.86 million shares. The 52-week range on ACAD shows that it touched its highest point at $33.99 and its lowest point at $17.56 during that stretch. It currently has a 1-year price target of $29.31. Beta for the stock currently stands at 0.37.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACAD was up-trending over the past week, with a rise of 0.43%, but this was down by -22.13% over a month. Three-month performance dropped to -41.80% while six-month performance fell -27.72%. The stock gained 0.33% in the past year, while it has lost -40.95% so far this year. A look at the trailing 12-month EPS for ACAD yields -0.38 with Next year EPS estimates of 1.27. For the next quarter, that number is 0.06. This implies an EPS growth rate of 280.61% for this year and 90.09% for next year.

Float and Shares Shorts:

At present, 164.65 million ACAD shares are outstanding with a float of 163.49 million shares on hand for trading. On Mar 15, 2024, short shares totaled 10.63 million, which was 6.45% higher than short shares on Feb 15, 2024. In addition to Mr. Stephen R. Davis J.D. as the firm’s President, CEO & Director, Mr. Mark C. Schneyer serves as its Executive VP & CFO.

Institutional Ownership:

Through their ownership of 99.37% of ACAD’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACAD since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, ACAD has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and ACAD currently yields $0.00. In the past year, ACAD’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, ACAD has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.